BLAINTRAVENOUSSOLUTION
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
Panzyga (immune globulin intravenous (human)) by Octapharma. Approved for primary immunodeficiency, immune thrombocytopenic purpura, multifocal motor neuropathy. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Panzyga is an intravenous immunoglobulin (IVIG) derived from pooled human plasma, approved by the FDA in November 2018. It is indicated for a broad range of conditions including primary immunodeficiencies, immune thrombocytopenic purpura, multifocal motor neuropathy, Kawasaki syndrome, and various inflammatory myopathies. The drug functions through antigen neutralization and immune modulation mechanisms inherent to polyclonal human immunoglobulins. Panzyga represents a mature therapeutic option in the IVIG market, competing against both branded IVIG products and emerging targeted immunotherapies.
$0.0BPart D
Mechanism of Action
Pharmacologic Class:
Antigen Neutralization
Worked on Panzyga at Octapharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.